Email:
global@GCP-ClinPlus.com
At the "Decennial" – the 10th New Drug Founders Annual Conference held yesterday in Shanghai – GCP ClinPlus was named to the "Best Enabling Service Partner" list. Chosen by an expert panel of senior industry leaders and institutions, the award recognizes service providers that have made outstanding contributions to China's biopharma innovation.
As the first Chinese CRO to offer integrated China-U.S.-EU development services, GCP ClinPlus stood out through 22 years of experience across more than 2,200 clinical studies. Projects in which the company has played a pivotal role have already yielded 210+ approved products, including megatrials enrolling over 20,000 subjects.
The tenth-anniversary event brought together top scientists, entrepreneurs, and investors from China and abroad to map out the next decade of industry growth. In this pivotal year for Chinese innovation, thought leaders explored transformative trends and injected fresh momentum into regional high-quality development.
The "Best Enabling Service Partner" honor is based on rigorous criteria spanning service quality, innovation, and industry impact—underscoring broad recognition of GCP ClinPlus' two-decade track record of clinical excellence.
GCP ClinPlus is accelerating digital and technological innovation. Its proprietary data-integration platform enables real-time, dynamic oversight of clinical trials—delivering flexible monthly, weekly, or even daily interim reports that markedly enhance data completeness and reliability.
Looking ahead, GCP ClinPlus is deepening its commitment to cell and gene therapy (CGT). Leveraging 22 years of cross-therapeutic-area expertise, the company is expanding CGT service breadth and depth to deliver end-to-end support for a growing roster of partners.
Going forward, GCP ClinPlus will continue to harness its data-science heritage to elevate clinical research standards and co-create next-generation CRO solutions. As Chinese innovation steps onto the global stage, GCP ClinPlus stands ready—empowering every milestone as "the trusted global clinical-research solutions provider."